Haemonetics Corp reports results for the quarter ended June 30 - Earnings Summary
Haemonetics Corp reports results for the quarter ended June 30 - Earnings Summary
Haemonetics Corp HAE.N reported quarterly adjusted earnings of $1.14 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.10. The mean expectation of eleven analysts for the quarter was for earnings of $1.08 per share. Wall Street expected results to range from $1.02 to $1.14 per share.
Revenue rose 5.6% to $339.38 million from a year ago; analysts expected $327.89 million.
Haemonetics Corp's reported EPS for the quarter was 72 cents.
The company reported quarterly net income of $33.01 million.
Haemonetics Corp shares had risen by 11.5% this quarter and gained 4.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Haemonetics Corp is $90.00, about 7.1% above its last closing price of $83.60
This summary was machine generated from LSEG data August 6 at 11:01 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 1.08 | 1.14 | Beat |
Mar. 31 2026 | 1.27 | 1.29 | Beat |
Dec. 31 2025 | 1.25 | 1.31 | Beat |
Sep. 30 2025 | 1.11 | 1.27 | Beat |
Recent news on Haemonetics
See all newsBrief: Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System
Haemonetics says FDA clears vascular closure device
US STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Haemonetics surges as CSL plans to move all US plasma centers to its devices